Broken String Biosciences appoints Gavin Burns as Vice President of Quality and Operations
November 22, 2023 – Biotechnology – Broken String Biosciences, CGTs, appointments
- Experienced quality assurance professional joins team to support ongoing strategic growth plans as the company expands access and capabilities of INDUCE-seq DNA break mapping platform
- Expansion to leadership team follows recent appointments of Vincent Smith as chief technology officer and Jessica Rich as vice president of Business Development
22 November 2023 — Cambridge, UK — Broken String Biosciences, a genomics company that has built a technology platform to drive the development of cell and gene therapies (CGTs) that are safer by design, today announced the appointment of Gavin Burns PhD, as vice president of Quality and Operations. With an extensive background leading quality assurance in the genomics sector, Gavin will be responsible for building and optimising Broken String’s teams, processes and systems. His appointment will enable the company to develop and scale its Next Generation Sequencing (NGS)-based DNA break-mapping platform, INDUCE-seq, furthering the technology’s capabilities in supporting gene-editing applications.
Felix Dobbs PhD, chief executive officer at Broken String Biosciences, commented: “Gavin’s expertise in quality strategy and implementing robust processes will be key to executing our growth plans as part of our Series A goals. As well as supporting scale-up operations in these areas, Gavin will ensure that our INDUCE-seq platform meets the quality needs of our partners who are developing the next generation of transformative gene editing therapies. We are thrilled to have Gavin on board as we build towards a future where gene editing therapies can be safely delivered to all who need it.”
Gavin Burns PhD, VP of Quality and Operations at Broken String Biosciences, said: “The INDUCE-seq technology offered by Broken String Biosciences has the potential to transform development of gene edited CGTs. I look forward to working closely with the rest of the team at Broken String Biosciences to support scale-up and growth at this exciting time, and ensure processes are optimised so that we can continue to deliver high quality and cutting-edge technology that meets the needs of our customers.”
About Broken String Biosciences
Broken String Biosciences’ technology platform, INDUCE-seq, supports the development of CGTs that are safer by design. INDUCE-seq is a Next Generation Sequencing (NGS)-based DNA break mapping platform that enables companies developing CGTs to measure and quantify the specificity of off-target genetic edits and to evaluate the associated genetic outcomes. The platform technology provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to unlock new therapeutic targets within the genome and to advance gene editing programmes.
Broken String Biosciences was spun out of Cardiff University in 2020 and completed a six-month residency at the Illumina Accelerator in Cambridge, UK. The company has raised financing of $20m to date from venture capital investors. To find out more, visit: www.brokenstringbio.com,
